Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid …
Over the last 12 months, insiders at Kiora Pharmaceuticals, Inc. have bought $95,206 and sold $0 worth of Kiora Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Kiora Pharmaceuticals, Inc. have bought $2.07M and sold $7.61M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Parsons Erin (director) — $25,669. TYLE PRAVEEN (director) — $19,800. Strem Brian M. (President and CEO) — $14,997.
The last purchase of 1,250 shares for transaction amount of $4,600 was made by Stengone Carmine N. (director) on 2024‑09‑11.
2024-09-11 | director | 1,250 0.0442% | $3.68 | $4,600 | -1.63% | |||
2024-09-10 | director | 3,000 0.1039% | $3.60 | $10,800 | -0.29% | |||
2024-08-19 | director | 5,000 0.165% | $3.96 | $19,800 | -11.63% | |||
2024-08-19 | director | 1,250 0.0402% | $3.86 | $4,825 | -11.63% | |||
2024-08-14 | CFO | 2,000 0.0667% | $3.21 | $6,420 | 0.00% | |||
2024-06-14 | Chief Development Officer | 1,431 0.0556% | $5.29 | $7,570 | -31.72% | |||
2024-06-14 | EVP Finance | 100 0.0039% | $5.25 | $525 | -31.72% | |||
2024-06-13 | President and CEO | 3,000 0.1101% | $5.00 | $14,997 | -24.38% | |||
2024-06-13 | director | 5,260 0.1885% | $4.88 | $25,669 | -24.38% | |||
2021-11-18 | President and CEO | 17,853 0.1764% | $1.41 | $25,173 | -68.88% | |||
2021-08-02 | Sale | 10 percent owner | 192,775 1.8717% | $2.40 | $463,046 | -69.80% | ||
2021-07-30 | Sale | 10 percent owner | 68,188 0.7096% | $2.69 | $183,562 | -70.83% | ||
2021-07-29 | Sale | 400,000 4.0311% | $3.00 | $1.2M | -74.57% | |||
2021-07-28 | Sale | 375,443 3.7408% | $3.28 | $1.23M | -76.79% | |||
2021-07-27 | Sale | 2.38M 31.3018% | $5.09 | $12.11M | -79.90% | |||
2021-01-06 | 1.53M 21.542% | $5.22 | $8M | -32.02% | ||||
2020-02-10 | 12,000 0.2683% | $6.04 | $72,480 | -18.43% | ||||
2020-02-06 | 11,000 0.2463% | $6.18 | $67,980 | -20.16% | ||||
2019-12-06 | Sale | director | 1,961 0.0619% | $6.93 | $13,590 | -27.54% | ||
2019-11-12 | Sale | director | 2,001 0.06% | $4.29 | $8,584 | +12.00% |
Strem Brian M. | President and CEO | 14531 0.4892% | $3.58 | 2 | 0 | <0.0001% |
Tosca Melissa | CFO | 13599 0.4578% | $3.58 | 2 | 0 | |
Daniels Eric Joseph | Chief Development Officer | 11222 0.3778% | $3.58 | 1 | 0 | |
Parsons Erin | director | 5260 0.1771% | $3.58 | 1 | 0 | |
TYLE PRAVEEN | director | 5014 0.1688% | $3.58 | 1 | 0 |